Codexis - CDXS Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CDXS shares.
View CDXS analyst ratings or view top-rated stocks.

5 brokerages have issued twelve-month price targets for Codexis' shares. Their CDXS share price forecasts range from $19.00 to $25.00. On average, they expect the company's share price to reach $21.33 in the next twelve months. This suggests a possible upside of 252.6% from the stock's current price.
View analysts price targets for CDXS or view top-rated stocks among Wall Street analysts.

Codexis' stock was trading at $31.27 at the beginning of 2022. Since then, CDXS stock has decreased by 80.7% and is now trading at $6.05.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our CDXS earnings forecast.

Codexis, Inc. (NASDAQ:CDXS) posted its earnings results on Thursday, August, 4th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.10. The biotechnology company earned $38.41 million during the quarter, compared to the consensus estimate of $37.86 million. Codexis had a negative trailing twelve-month return on equity of 11.63% and a negative net margin of 14.03%. The business's revenue was up 50.9% compared to the same quarter last year. During the same period last year, the business earned ($0.07) earnings per share.

Codexis issued an update on its FY 2022 earnings guidance on Thursday, September, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $135.00 million-$141.00 million, compared to the consensus revenue estimate of $137.67 million.

25 employees have rated Codexis Chief Executive Officer John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CDXS stock can currently be purchased for approximately $6.05.

Codexis (NASDAQ:CDXS) has a market capitalization of $396.21 million and generates $104.75 million in revenue each year. The biotechnology company earns $-21,280,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis.

The company employs 261 workers across the globe.

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.codexis.com. The biotechnology company can be reached via phone at (650) 421-8100, via email at ir@codexis.com, or via fax at 650-421-8102.